NEUROCRINE BIOSCIENCES ($NBIX) posted quarterly earnings results for Q1 2026 on Tuesday, May 5th. The company reported earnings of $1.94 per share, beating estimates of $1.17 by $0.77. The company also reported revenue of $814,500,000, beating estimates of $785,600,613 by $28,899,387.
Stock price change since market close: +2.76%
You can see Quiver Quantitative's $NBIX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NEUROCRINE BIOSCIENCES Insider Trading Activity
NEUROCRINE BIOSCIENCES insiders have traded $NBIX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KYLE GANO (Chief Executive Officer) has made 0 purchases and 3 sales selling 36,700 shares for an estimated $4,873,049.
- WILLIAM H RASTETTER sold 18,000 shares for an estimated $2,732,689
- GARY A LYONS sold 15,000 shares for an estimated $2,289,082
- GEORGE J MORROW sold 15,000 shares for an estimated $2,150,512
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 6,190 shares for an estimated $945,701.
- ERIC BENEVICH (Chief Commercial Officer) sold 5,970 shares for an estimated $905,880
- DARIN LIPPOLDT (Chief Legal Officer) sold 4,376 shares for an estimated $698,615
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
NEUROCRINE BIOSCIENCES Hedge Fund Activity
We have seen 377 institutional investors add shares of NEUROCRINE BIOSCIENCES stock to their portfolio, and 300 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,338,472 shares (-76.4%) from their portfolio in Q4 2025, for an estimated $331,665,483
- PRICE T ROWE ASSOCIATES INC /MD/ removed 994,491 shares (-34.7%) from their portfolio in Q4 2025, for an estimated $141,048,658
- CITADEL ADVISORS LLC removed 713,528 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $101,199,676
- TWO SIGMA ADVISERS, LP added 693,819 shares (+466.4%) to their portfolio in Q4 2025, for an estimated $98,404,348
- TWO SIGMA INVESTMENTS, LP added 637,246 shares (+183.3%) to their portfolio in Q4 2025, for an estimated $90,380,600
- MORGAN STANLEY removed 617,559 shares (-33.8%) from their portfolio in Q4 2025, for an estimated $87,588,392
- MILLENNIUM MANAGEMENT LLC removed 534,344 shares (-54.7%) from their portfolio in Q4 2025, for an estimated $75,786,009
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
NEUROCRINE BIOSCIENCES Analyst Ratings
Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
- Needham issued a "Buy" rating on 02/12/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Stifel issued a "Buy" rating on 12/11/2025
- TD Cowen issued a "Buy" rating on 12/05/2025
To track analyst ratings and price targets for NEUROCRINE BIOSCIENCES, check out Quiver Quantitative's $NBIX forecast page.
NEUROCRINE BIOSCIENCES Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 17 analysts offer price targets for $NBIX in the last 6 months, with a median target of $177.0.
Here are some recent targets:
- Marc Goodman from Leerink Partners set a target price of $170.0 on 04/22/2026
- Jeffrey Hung from Morgan Stanley set a target price of $185.0 on 04/10/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $215.0 on 04/07/2026
- Laura Chico from Wedbush set a target price of $166.0 on 04/07/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $200.0 on 04/07/2026
- Yigal Nochomovitz from Citigroup set a target price of $242.0 on 04/07/2026
- Ami Fadia from Needham set a target price of $185.0 on 04/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
